We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

By LabMedica International staff writers
Posted on 28 Mar 2024
Print article
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane inside the ovary. Often discovered by chance in women without symptoms, ovarian cysts can also be detected during evaluations for pelvic pain. Surgical removal is a common treatment, with 5%-10% of women with ovarian cysts undergoing surgery. Of these, 13%-21% are found to have cancer upon intra-operative evaluation. The Frozen Section procedure for intra-operative evaluation that involves the slicing and microscopic examination of freeze-dried ovarian tissue aids in this determination but suffers from limitations such as unavailability, a lengthy process of up to 60 minutes, and low accuracy. The need for a swift method to differentiate between benign and malignant cysts during surgery is critical to inform management and treatment choices effectively.

INEX Innovate (Singapore) has now introduced the OvaCis Rapid Test, a novel intraoperative in vitro diagnostic (IVD) device. This test, with the ability to rapidly distinguish benign from malignant ovarian cysts within just 15 minutes, provides surgeons with immediate diagnostic data. This enables them to make quicker, more informed decisions and reduce unnecessary surgical procedures. The OvaCis Rapid Test has received regulatory approval from the Health Sciences Authority (HSA) in Singapore and is also CE-marked, and MHRA, UK registered.

Related Links:
INEX Innovate

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.